Name: Contrast Media Market By Type (lodinated Contrast Media), Form (Liquid, Powder), Modality (X-ray, MRI, Ultrasound), Route of Administration (Oral, Rectal), Indication (Cancer, Neurological, GI, Musculoskeletal Disorders) & Region - Global Forecast to 2031
Brand: MarketsandMarkets
SKU: MD3577
Price: 4950 USD
Availability: InStock

報告摘要

The global contrast media market is projected to reach USD 12.08 billion by 2031 from USD 7.65 billion in 2025, at a CAGR of 7.9% from 2026 to 2031. The contrast media market is mainly driven by innovation in contrast agent formulations and the development of targeted and activatable contrast agents, which enhance the accuracy of imaging studies and meet the increasing demand for precise diagnostics. Additionally, government investments in healthcare initiatives, such as expanding diagnostic imaging services and establishing framework agreements, support access to advanced imaging options. Moreover, the rising prevalence of chronic diseases like cancer and cardiovascular conditions necessitates contrast imaging studies for early detection, monitoring, and treatment planning. “The cardiovascular disease segment held the largest share of the market in 2026.” By indication, the contrast media market is segmented into cardiovascular disease, cancer, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. The cardiovascular disease segment held the largest market share in 2026, driven by the high volume of diagnostic and interventional procedures such as coronary angiography, CT angiography, and cardiac catheterization. The increasing prevalence of heart disorders worldwide has made contrast-enhanced imaging a standard practice for accurate diagnosis and treatment planning. Additionally, the urgent need for real-time visualization of vessels during cardiac surgery has sustained a steady demand for contrast agents. Furthermore, the introduction of advanced imaging technology in cardiology is a key driver of this segment's dominance. “The interventional cardiology segment is projected to register the highest CAGR during the forecast period.” By application, the contrast media market is segmented into radiology, interventional radiology, and interventional cardiology. The interventional cardiology segment is expected to have the highest CAGR from 2026 to 2031, driven by the rapid growth of minimally invasive cardiac procedures, including angioplasty, stent placement, and catheter-based interventions. The number of procedures is increasing because of a rise in coronary artery disease and lifestyle-related cardiac disorders. Additionally, the development of catheterization labs and imaging-guided technologies has led to greater use of contrast agents in cardiac interventions. Furthermore, the segment is being further supported by patients' increasing preference for quick recovery and shorter hospital stays. “The market in the Asia Pacific region is expected to witness the highest growth during the forecast period.” The rapid development of healthcare infrastructure in nations such as China, India, and Japan is driving growth in the contrast media market in the Asia Pacific region. Access to contrast-enhanced procedures is becoming better due to rising healthcare costs and the growing use of sophisticated diagnostic imaging systems. Imaging volumes are also being driven throughout the region by the rising prevalence of chronic illnesses and the growth of medical tourism. Additionally, the market is expanding faster due to the government's strong support for hospital modernization and early diagnosis. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16% • By Designation: C-level–10%, Director-level–14%, and Others–76% • By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3% The prominent players in the contrast media market are Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (US), Lantheus Medical Imaging (US), GE HealthCare (US), Unijules Life Sciences Ltd. (India), J.B. Chemicals & Pharmaceuticals Limited (India), Sanochemia Pharmazeutika GmbH (Germany), Taejoon Pharm Co., Ltd. (South Korea), Jodas Expoim (India), iMax Diagnostic Imaging Limited (Ireland), YZJ Group (China), Beijing Beilu Pharmaceutical Co., Ltd. (China), and Livealth Biopharma Pvt. Ltd. (India) among others. Research Coverage This report studies the contrast media market based on type, indication, modality, route of administration, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets by growth trends. It forecasts market segment revenue across five main regions (and the respective countries in these regions). Reasons to Buy the Report The report will help market leaders/new entrants with information on the closest approximations of revenue for the overall contrast media market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides insights into key drivers, restraints, challenges, and opportunities. This report provides insights into the following pointers: • Analysis of key drivers (Rising number of contrast- mediated scan, Advancements in contrast agent formulations, increasing development of targeted and activatable contrast agents for precision diagnostics and Government Investment and NHS Framework Agreements Supporting Diagnostic Imaging Expansion), restraints (Risk of Adverse Reactions, High Cost of Imaging Procedures, Limited circulation time and stability of contrast agents, environmental persistence of gadolinium-based contrast agents), opportunities (Growth of Interventional Radiology and Image-Guided Procedures, Development of Microbubble and Ultrasound Contrast Agents, Expansion of Contrast-Enhancced Ultrasound (CEUS) Applications in Pediatric Abdominal Imaging), and challenges (Workforce Shortages in Radiology, Supply Chain Vulnerabilities, Complex Regulatory Approval Pathways for Novel and Multimodal Contrast Agents) influencing the growth of the contrast media market • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the contrast media market • Market Development: Comprehensive information about lucrative markets–the report analyses the contrast media market across varied regions • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the contrast media market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (US), GE HealthCare (US), and others.

目錄 Table of Contents

1 INTRODUCTION 24 1.1 OBJECTIVES OF THE STUDY 24 1.2 MARKET DEFINITION 24 1.3 MARKET SCOPE 25 1.3.1 MARKETS COVERED AND REGIONS CONSIDERED 25 1.3.2 INCLUSIONS & EXCLUSIONS 26 1.3.3 YEARS CONSIDERED 26 1.3.4 CURRENCY CONSIDERED 27 1.4 MARKET STAKEHOLDERS 27 1.5 SUMMARY OF CHANGES 27 2 EXECUTIVE SUMMARY 29 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 29 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 31 2.3 DISRUPTIVE TRENDS IN CONTRAST MEDIA MARKET 32 2.4 HIGH GROWTH SEGMENTS 33 3 PREMIUM INSIGHTS 35 3.1 CONTRAST MEDIA MARKET OVERVIEW 35 3.2 CONTRAST MEDIA MARKET, BY REGION 36 3.3 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY COUNTRY AND END USER 37 3.4 GEOGRAPHIC SNAPSHOT OF CONTRAST MEDIA MARKET 38 4 MARKET OVERVIEW 39 4.1 INTRODUCTION 39 4.2 MARKET DYNAMICS 39 4.2.1 DRIVERS 41 4.2.1.1 Advancements in contrast agent formulations 41 4.2.1.2 Precision Diagnostics Enabled by Targeted and Activatable Contrast Agents 42 4.2.1.3 Government Investments and Healthcare Procurement Initiatives 42 4.2.1.4 Rising number of contrast-mediated scans 43 4.2.2 RESTRAINTS 43 4.2.2.1 Limited Circulation Time and Stability of Certain Contrast Agents 43 4.2.2.2 Environmental persistence of gadolinium-based contrast agents 43 4.2.3 OPPORTUNITIES 44 4.2.3.1 Expansion of Multimodal Imaging Technologies 44 4.2.3.2 Expansion of Contrast-enhanced ultrasound (CEUS) applications in pediatric imaging 45 4.2.3.3 Increasing demand for low-dose, high-relaxivity contrast agents for neonates and infants 46 4.2.4 CHALLENGES 46 4.2.4.1 Safety and toxicity concerns associated with gadolinium and nanoparticle-based contrast agents 46 4.2.4.2 Complex regulatory approval pathways for novel and multimodal contrast agents 47 4.2.4.3 Complexity in scalable synthesis and standardization of nanoparticle-based contrast agents 47 4.3 UNMET NEEDS 47 4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 48 5 INDUSTRY TRENDS 50 5.1 PORTER’S FIVE FORCES ANALYSIS 50 5.2 MACROECONOMIC INDICATORS 52 5.2.1 INTRODUCTION 52 5.2.2 HEALTHCARE EXPENDITURE AND INFRASTRUCTURE OUTLOOK 52 5.2.2.1 Macroeconomic outlook for NORTH AMERICA 52 5.2.3 MACROECONOMIC OUTLOOK FOR EUROPE 52 5.2.4 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 53 5.2.5 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 53 5.2.6 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 54 5.3 SUPPLY CHAIN ANALYSIS 54 5.4 ECOSYSTEM ANALYSIS 55 5.5 PRICING ANALYSIS 57 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION 57 5.5.2 AVERAGE SELLING PRICE OF CONTRAST MEDIA PRODUCTS, BY KEY PLAYER 60 5.5.3 AVERAGE SELLING PRICE TREND OF CONTRAST MEDIA PRODUCTS, BY KEY PLAYER, 2024 60 5.6 TRADE DATA ANALYSIS 61 5.6.1 IMPORT DATA (HS CODE 300630) 61 5.6.2 EXPORT DATA (HS CODE 300630) 61 5.7 KEY CONFERENCES & EVENTS, 2026–2027 62 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63 5.9 INVESTMENT & FUNDING SCENARIO 64 5.10 CASE STUDY ANALYSIS 65 5.10.1 CASE STUDY 1: MACROCYCLIC CONTRAST AGENTS FOR IMPROVED MRI SAFETY 65 5.10.2 CASE STUDY 2: IODINATED CONTRAST MEDIA OPTIMIZATION IN CT IMAGING 66 5.10.3 CASE STUDY 3: LOW-DOSE MRI CONTRAST AGENT FOR PEDIATRIC MRI IMAGING 66 5.11 IMPACT OF 2025 US TARIFF― CONTRAST MEDIA MARKET 66 5.11.1 INTRODUCTION 66 5.11.2 KEY TARIFF RATES 67 5.11.3 PRICE IMPACT ANALYSIS 67 5.11.4 IMPACT ON COUNTRY/REGION 68 5.11.5 IMPACT ON END USERS 69 6 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 70 6.1 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 70 6.1.1 BUYING CRITERIA 71 6.1.2 DECISION-MAKING PROCESS 72 6.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 73 6.3 UNMET NEEDS FROM END USERS 73 6.3.1 UNMET NEEDS FROM END USERS 75 7 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, AND AI ADOPTION 76 7.1 KEY TECHNOLOGIES 76 7.1.1 CONTRAST-ENHANCED ULTRASOUND (CEUS) ADVANCEMENTS 76 7.1.1.1 Targeted and molecular contrast agents 76 7.1.1.2 Advanced gadolinium-based agents and hyperpolarized techniques 77 7.1.2 COMPLEMENTARY TECHNOLOGIES 77 7.1.2.1 Automated contrast injector systems 77 7.2 PATENT ANALYSIS 78 7.2.1 CONTRAST MEDIA MARKET: LIST OF PATENTS 79 7.3 FUTURE APPLICATIONS 79 7.4 IMPACT OF AI/GEN AI ON CONTRAST MEDIA MARKET 80 7.4.1 TOP USE CASES AND MARKET POTENTIAL 80 7.4.2 BEST PRACTICES IN CONTRAST MEDIA. 81 7.4.3 CASE STUDIES OF AI IMPLEMENTATION IN CONTRAST MEDIA MARKET 82 7.4.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 82 7.4.5 CLIENT READINESS TO ADOPT GENERATIVE AI IN CONTRAST MEDIA MARKET 83 7.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 84 8 CONTRAST MEDIA MARKET, BY TYPE 85 8.1 INTRODUCTION 86 8.2 IODINATED CONTRAST MEDIA 86 8.2.1 RISING ADOPTION OF CT IMAGING INCREASES DEMAND 86 8.3 GADOLINIUM-BASED CONTRAST MEDIA 87 8.3.1 SAFETY CONCERNS ASSOCIATED WITH GADOLINIUM-BASED CONTRAST AGENTS RESTRAIN MARKET GROWTH 87 8.4 MICROBUBBLE CONTRAST MEDIA 89 8.4.1 GROWING PHYSICIAN PREFERENCE FOR CONTRAST-ENHANCED ULTRASOUND DRIVES ADOPTION 89 8.5 BARIUM-BASED CONTRAST MEDIA 90 8.5.1 ADVERSE EFFECTS ASSOCIATED WITH BARIUM SULFATE CONTRAST MEDIA LIMIT CLINICAL USAGE 90 9 CONTRAST MEDIA MARKET, BY FORM 92 9.1 INTRODUCTION 93 9.2 LIQUID 93 9.2.1 CONVENIENCE OF USE IN HOSPITALS AND DIAGNOSTIC CENTERS TO DRIVE MARKET GROWTH 93 9.3 POWDER 94 9.3.1 CONVENIENT HANDLING, STORAGE, AND TRANSPORTATION DRIVES INCREASED ADOPTION 94 9.4 OTHER FORMS 95 10 CONTRAST MEDIA MARKET, BY MODALITY 97 10.1 INTRODUCTION 98 10.2 X-RAY 98 10.2.1 DEVELOPMENT OF SAFER, LOW-CONCENTRATION CONTRAST AGENTS FOR X-RAY - KEY OPPORTUNITY 98 10.3 CT 100 10.3.1 INCREASING NUMBER OF CT EXAMINATIONS TO PROPEL MARKET 100 10.4 MRI 101 10.4.1 INCREASING FOCUS ON NEXT-GENERATION GADOLINIUM-BASED CONTRAST AGENTS TO ENHANCE SAFETY AND IMAGING PERFORMANCE 101 10.5 ULTRASOUND 103 10.5.1 FLEXIBLE AND LOW-COST DIAGNOSTIC IMAGING MODALITY – KEY FACTORS DRIVING MARKET GROWTH 103 11 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION 105 11.1 INTRODUCTION 106 11.2 INTRAVASCULAR ROUTE 106 11.2.1 INCREASING CLINICAL RELIANCE FOR ENHANCED DIAGNOSTIC IMAGING AND TREATMENT OUTCOMES TO DRIVE SEGMENT 106 11.2.1.1 Intravenous (IV) route 107 11.2.1.2 Intra-arterial (IA) route 108 11.3 ORAL ROUTE 109 11.3.1 ENHANCING GASTROINTESTINAL VISUALIZATION WITH ORAL CONTRAST AGENTS IN DIAGNOSTIC IMAGING 109 11.4 RECTAL ROUTE 111 11.4.1 RISING DEMAND FOR ACCURATE POST-SURGICAL COMPLICATION DETECTION TO DRIVE ADOPTION 111 11.5 OTHER ROUTES 112 12 CONTRAST MEDIA MARKET, BY INDICATION 114 12.1 INTRODUCTION 115 12.2 CARDIOVASCULAR DISEASE 115 12.2.1 HIGH BURDEN OF CVD TO DRIVE MARKET 115 12.3 CANCER 116 12.3.1 ADVANCED ONCOLOGIC DIAGNOSTICS THROUGH CONTRAST-ENHANCED ULTRASOUND IMAGING TO BOOST SEGMENT 116 12.4 GASTROINTESTINAL DISORDERS 117 12.4.1 EXPANDING ROLE OF CEUS IN PEDIATRIC GASTROINTESTINAL DISORDERS AND NEONATAL IMAGING TO PROPEL GROWTH 117 12.5 MUSCULOSKELETAL DISORDERS 118 12.5.1 RISING INCIDENCE OF WORK-RELATED MUSCULOSKELETAL DISORDERS TO SUPPORT MARKET GROWTH 118 12.6 NEUROLOGICAL DISORDERS 120 12.6.1 INCREASING BURDEN OF NEUROLOGICAL DISORDERS DRIVES DEMAND 120 12.7 NEPHROLOGICAL DISORDERS 121 12.7.1 RISING PREVALENCE OF END-STAGE RENAL DISEASE TO DRIVE DEMAND 121 13 CONTRAST MEDIA MARKET, BY APPLICATION 123 13.1 INTRODUCTION 124 13.2 RADIOLOGY 124 13.2.1 GROWING NUMBER OF DIAGNOSTIC PROCEDURES TO DRIVE MARKET 124 13.3 INTERVENTIONAL RADIOLOGY 125 13.3.1 RISING ADOPTION OF MINIMALLY INVASIVE INTERVENTIONS TO DRIVE MARKET 125 13.4 INTERVENTIONAL CARDIOLOGY 126 13.4.1 RISING INCIDENCE OF CARDIAC DISEASES TO DRIVE MARKET 126 14 CONTRAST MEDIA MARKET, BY END USER 128 14.1 INTRODUCTION 129 14.2 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS 129 14.2.1 INCREASING ADOPTION OF DIAGNOSTIC IMAGING MODALITIES TO DRIVE MARKET 129 14.3 DIAGNOSTIC IMAGING CENTERS 131 14.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO PROPEL MARKET 131 15 CONTRAST MEDIA MARKET, BY REGION 133 15.1 INTRODUCTION 134 15.2 NORTH AMERICA 134 15.2.1 US 139 15.2.1.1 Rising incidence of chronic diseases to drive market 139 15.2.2 CANADA 140 15.2.2.1 Growth influenced by supply expansion and increasing market competition 140 15.3 EUROPE 141 15.3.1 GERMANY 144 15.3.1.1 Presence of well-established players to support market growth 144 15.3.2 FRANCE 145 15.3.2.1 Growth supported by high imaging utilization and expanding clinical applications 145 15.3.3 UK 146 15.3.3.1 Innovation in next-generation MRI contrast agents to drive growth 146 15.3.4 ITALY 148 15.3.4.1 Growth driven by innovation in ultrasound contrast agents and product expansion 148 15.3.5 SPAIN 149 15.3.5.1 Shift toward safer and cost-efficient low-osmolar contrast agents in CT imaging to boost market 149 15.3.6 REST OF EUROPE 149 15.4 ASIA PACIFIC 150 15.4.1 CHINA 154 15.4.1.1 Strong domestic capabilities and strategic supply chain position drive market growth 154 15.4.2 JAPAN 155 15.4.2.1 Advanced imaging infrastructure and strategic industry expansion to drive demand 155 15.4.3 INDIA 156 15.4.3.1 Expanding domestic manufacturing and increasing imaging demand to propel market growth 156 15.4.4 AUSTRALIA 157 15.4.5 SOUTH KOREA 158 15.4.5.1 AI-driven imaging optimization and rising early-onset cancer burden reshaping demand 158 15.4.6 REST OF ASIA PACIFIC 159 15.4.7 LATIN AMERICA 160 15.4.7.1 Cost-sensitive procurement and rising CT imaging volumes drive contrast media utilization 160 15.4.8 BRAZIL 164 15.4.8.1 Rising disease burden drives demand amid safety and access challenges 164 15.4.9 MEXICO 165 15.4.9.1 Rising CKD burden, low healthcare spending, and environmental concerns influence contrast media utilization 165 15.4.10 REST OF LATIN AMERICA 166 15.4.10.1 Fragmented access, import dependence, and public–private imbalance shaping contrast media utilization 166 15.4.11 MIDDLE EAST & AFRICA 166 15.4.11.1 High burden of chronic diseases to drive market 166 15.4.12 GCC COUNTRIES 170 15.4.12.1 Increasing government investments in healthcare sector and growing pharmaceuticals industry to drive market 170 15.4.13 REST OF MIDDLE EAST & AFRICA 171 15.4.13.1 Import dependence and unbalanced imaging access driving selective contrast media utilization 171 16 COMPETITIVE LANDSCAPE 173 16.1 INTRODUCTION 173 16.2 KEY PLAYERS’ STRATEGIES/RIGHT TO WIN 173 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CONTRAST MEDIA MARKET 174 16.3 REVENUE ANALYSIS OF KEY PLAYERS IN CONTRAST MEDIA MARKET 2021–2025 176 16.4 MARKET SHARE ANALYSIS, 2024 177 16.4.1 MARKET RANKING OF KEY PLAYERS, 2024 179 16.5 COMPANY VALUATION & FINANCIAL METRICS 179 16.5.1 FINANCIAL METRICS 179 16.5.2 COMPANY VALUATION 180 16.6 BRAND/PRODUCT COMPARISON 181 16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 182 16.7.1 STARS 182 16.7.2 PERVASIVE PLAYERS 182 16.7.3 EMERGING LEADERS 182 16.7.4 PARTICIPANTS 182 16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 184 16.7.5.1 Company footprint 184 16.7.5.2 Region footprint 185 16.7.5.3 Product type footprint 186 16.7.5.4 MODALITY FOOTPRINT 187 16.7.5.5 ROUTE OF ADMINISTRATION FOOTPRINT 188 16.7.5.6 INDICATION FOOTPRINT 189 16.7.5.7 END USER FOOTPRINT 190 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 191 16.8.1 PROGRESSIVE COMPANIES 191 16.8.2 RESPONSIVE COMPANIES 191 16.8.3 DYNAMIC COMPANIES 191 16.8.4 STARTING BLOCKS 191 16.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2025 193 16.8.5.1 CONTRAST MEDIA MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMEs 194 16.9 COMPETITIVE SCENARIO 195 16.9.1 PRODUCT LAUNCHES & APPROVALS 195 16.9.2 DEALS 196 16.9.3 EXPANSIONS 196 17 COMPANY PROFILES 197 17.1 KEY PLAYERS 197 17.1.1 GE HEALTHCARE 197 17.1.1.1 Business overview 197 17.1.1.2 Products offered 199 17.1.1.3 Recent developments 199 17.1.1.3.1 Product launches 199 17.1.1.4 MnM view 200 17.1.1.4.1 Key strengths 200 17.1.1.4.2 Strategic choices 200 17.1.1.4.3 Weaknesses & competitive threats 200 17.1.2 BRACCO IMAGING 201 17.1.2.1 Business overview 201 17.1.2.2 Products offered 201 17.1.2.3 Recent developments 203 17.1.2.3.1 Product launches 203 17.1.2.3.2 Deals 203 17.1.2.4 MnM view 204 17.1.2.4.1 Key strengths 204 17.1.2.4.2 Strategic choices 204 17.1.2.4.3 Weaknesses & competitive threats 204 17.1.3 BAYER AG 205 17.1.3.1 Business overview 205 17.1.3.2 Products offered 206 17.1.3.3 Recent developments 207 17.1.3.3.1 Expansions 207 17.1.3.4 MnM view 207 17.1.3.4.1 Key strengths 207 17.1.3.4.2 Strategic choices 207 17.1.3.4.3 Weaknesses & competitive threats 208 17.1.4 GUERBET 209 17.1.4.1 Business overview 209 17.1.4.2 Products offered 210 17.1.4.3 Recent developments 211 17.1.4.3.1 Product approvals 211 17.1.4.4 MnM view 211 17.1.4.4.1 Key strengths 211 17.1.4.4.2 Strategic choices 212 17.1.4.4.3 Weaknesses & competitive threats 212 17.1.5 LANTHEUS HOLDINGS, INC. 213 17.1.5.1 Business overview 213 17.1.5.2 Products offered 214 17.1.5.3 MnM view 214 17.1.5.3.1 Key strengths 214 17.1.5.3.2 Strategic choices 215 17.1.5.3.3 Weaknesses & competitive threats 215 17.1.6 UNIJULES LIFE SCIENCES LTD. 216 17.1.6.1 Business overview 216 17.1.6.2 Products offered 217 17.1.7 J.B. CHEMICALS & PHARMACEUTICALS LIMITED 218 17.1.7.1 Business overview 218 17.1.7.2 Products offered 219 17.1.8 SANOCHEMIA PHARMAZEUTIKA 221 17.1.8.1 Business overview 221 17.1.8.2 Products offered 222 17.1.9 TAEJOON PHARM CO., LTD. 223 17.1.9.1 Business overview 223 17.1.9.2 Products offered 223 17.1.10 JODAS EXPOIM 224 17.1.10.1 Business overview 224 17.1.10.2 Products offered 225 17.1.11 IMAX DIAGNOSTIC IMAGING LIMITED 226 17.1.11.1 Business overview 226 17.1.11.2 Products offered 226 17.1.11.3 Pipeline products 227 17.1.12 YANGTZE RIVER PHARMACEUTICAL GROUP 228 17.1.12.1 Business overview 228 17.1.12.2 Pipeline products 229 17.1.13 LIVEALTH 230 17.1.13.1 Business overview 230 17.1.13.2 Products offered 230 17.1.14 BEIJING BEILU PHARMACEUTICAL CO., LTD. 232 17.1.14.1 Business overview 232 17.1.14.2 Products offered 232 17.1.14.3 Recent developments 233 17.2 OTHER PLAYERS 235 17.2.1 ARCO LIFESCIENCES (I) PVT. LTD. 235 17.2.2 STANEX DRUGS & CHEMICALS PVT. LTD. 236 17.2.3 ONKO İLAÇ SAN. VE TIC. A.Ş. 237 17.2.4 FRESENIUS KABI 238 17.2.5 BIEM ILAC SAN. VE 239 17.2.6 ADVACARE PHARMA 240 17.2.7 FUJIFILM WAKO PURE CHEMICAL CORPORATION 241 17.2.8 UNISPIRE BIOPHARMA PRIVATE LIMITED 242 17.2.9 TRIVITRON HEALTHCARE 242 17.2.10 NANOPET PHARMA GMBH 243 18 RESEARCH METHODOLOGY 244 18.1 RESEARCH DATA 244 18.2 RESEARCH DESIGN 245 18.2.1 SECONDARY RESEARCH 245 18.2.1.1 Objectives of secondary research 246 18.2.1.2 Key data from secondary sources 247 18.2.2 PRIMARY RESEARCH 247 18.2.2.1 Objectives of primary research 248 18.2.2.2 Key industry insights 249 18.3 MARKET SIZE ESTIMATION METHODOLOGY 250 18.3.1 BOTTOM-UP APPROACH 251 18.3.1.1 Approach 1: Company revenue estimation approach 251 18.3.1.2 Approach 4: Primary interviews 252 18.3.2 TOP-DOWN APPROACH 252 18.4 MARKET BREAKDOWN AND DATA TRIANGULATION 255 18.5 MARKET SHARE ASSESSMENT 255 18.6 RESEARCH ASSUMPTIONS 256 18.7 RESEARCH LIMITATIONS 256 18.8 RISK ASSESSMENT 257 19 APPENDIX 258 19.1 DISCUSSION GUIDE 258 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 263 19.3 CUSTOMIZATION OPTIONS 265 19.4 RELATED REPORTS 265 19.5 AUTHOR DETAILS 266

圖表清單 List of Tables & Figures

TABLE 1 CONTRAST MEDIA MARKET: INCLUSIONS AND EXCLUSIONS 26 TABLE 2 CONTRAST MEDIA MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 40 TABLE 3 KEY TECHNOLOGICAL ADVANCEMENTS IN CONTRAST AGENT FORMULATIONS AND THEIR CLINICAL BENEFITS 41 TABLE 4 EMERGING TARGETED AND ACTIVATABLE CONTRAST AGENTS SUPPORTING PRECISION DIAGNOSTICS 42 TABLE 5 EMERGING AND CLINICAL APPLICATIONS OF CONTRAST-ENHANCED ULTRASOUND (CEUS) IN PEDIATRIC ABDOMINAL IMAGING 45 TABLE 6 CONTRAST AGENT MARKET: UNMET NEEDS 47 TABLE 7 STRATEGIC MOVES BY TIER 1, TIER 2, AND TIER 3 PLAYERS IN CONTRAST MEDIA MARKET 48 TABLE 8 CONTRAST MEDIA MARKET: PORTER’S FIVE FORCES 50 TABLE 9 NORTH AMERICA: MACROECONOMIC OUTLOOK 52 TABLE 10 EUROPE: MACROECONOMIC OUTLOOK 53 TABLE 11 ASIA PACIFIC: MACROECONOMIC INDICATORS 53 TABLE 12 LATIN AMERICA: MACROECONOMIC OUTLOOK 54 TABLE 13 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 54 TABLE 14 CONTRAST MEDIA MARKET: ROLE OF ECOSYSTEM 56 TABLE 15 AVERAGE SELLING PRICE OF CONTRAST MEDIA PRODUCT TYPES, BY REGION, 2024–2026(USD) 59 TABLE 16 AVERAGE SELLING PRICE TREND OF CONTRAST MEDIA PRODUCTS, BY KEY PLAYER, (USD) 60 TABLE 17 IMPORT DATA FOR HS CODE 300630, BY COUNTRY, 2021–2025 (USD THOUSAND) 61 TABLE 18 EXPORT DATA FOR HS CODE 300630 BY COUNTRY, 2021–2025 (USD THOUSAND) 61 TABLE 19 CONTRAST MEDIA MARKET: KEY CONFERENCES & EVENTS (2026–2027) 62 TABLE 20 CONTRAST MEDIA APPLICATION IN MRI SAFETY AND STABILITY 65 TABLE 21 CONTRAST MEDIA APPLICATION IN CT IMAGING OPTIMIZATION 66 TABLE 22 CONTRAST MEDIA APPLICATION IN PEDIATRIC MRI IMAGING 66 TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES IN MEDTECH INDUSTRY 67 TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTRAST MEDIA MARKET, BY PRODUCT 71 TABLE 25 KEY BUYING CRITERIA FOR CONTRAST MEDIA MARKET, BY END USER 72 TABLE 26 CONTRAST MEDIA MARKET: UNMET NEED ANALYSIS 74 TABLE 27 KEY AGENTS USED IN CONTRAST-ENHANCED ULTRASOUND (CEUS) 76 TABLE 28 CONTRAST MEDIA MARKET: KEY PATENTS, 2016–2020 79 TABLE 29 KEY COMPANIES IMPLEMENTING AI IN CONTRAST MEDIA ECOSYSTEM 82 TABLE 30 CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 86 TABLE 31 IODINATED CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 87 TABLE 32 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 88 TABLE 33 MICROBUBBLE CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 90 TABLE 34 BARIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 91 TABLE 35 CONTRAST MEDIA MARKET, BY FORM, 2024–2031 (USD MILLION) 93 TABLE 36 LIQUID CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 94 TABLE 37 POWDER CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 95 TABLE 38 OTHER FORMS: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 96 TABLE 39 CONTRAST MEDIA MARKET, BY MODALITY, 2024–2031 (USD MILLION) 98 TABLE 40 ENGLAND: COUNT OF X-RAY IMAGING ACTIVITY ON NHS PATIENTS, MAY 2023–MAY 2024 99 TABLE 41 X-RAY: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 99 TABLE 42 ENGLAND: COUNT OF CT IMAGING ACTIVITY ON NHS PATIENTS, MAY 2023–MAY 2024 100 TABLE 43 CT: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 101 TABLE 44 ENGLAND: COUNT OF MRI IMAGING ACTIVITY ON NHS PATIENTS, MAY 2023–MAY 2024 102 TABLE 45 MRI: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 102 TABLE 46 ENGLAND: COUNT OF ULTRASOUND IMAGING ACTIVITY ON NHS PATIENTS, MAY 2023–MAY 2024 104 TABLE 47 ULTRASOUND: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 104 TABLE 48 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 106 TABLE 49 INTRAVASCULAR ROUTE: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 107 TABLE 50 IV ROUTE: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 108 TABLE 51 IA ROUTE: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 109 TABLE 52 TYPES OF ORAL CT CONTRAST AGENTS, INCLUDING AGENTS CURRENTLY AVAILABLE AND AGENTS UNDER DEVELOPMENT 110 TABLE 53 ORAL ROUTE: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 111 TABLE 54 RECTAL ROUTE: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 112 TABLE 55 OTHER ROUTES: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 113 TABLE 56 CONTRAST MEDIA MARKET, BY INDICATION, 2024–2031 (USD MILLION) 115 TABLE 57 CARDIOVASCULAR DISEASE: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 116 TABLE 58 CANCER: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 117 TABLE 59 GASTROINTESTINAL DISORDERS: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 60 MUSCULOSKELETAL DISORDERS: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 61 NEUROLOGICAL DISORDERS: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 121 TABLE 62 NEPHROLOGICAL DISORDERS: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 63 CONTRAST MEDIA MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 124 TABLE 64 RADIOLOGY: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 65 INTERVENTIONAL RADIOLOGY: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 66 INTERVENTIONAL CARDIOLOGY: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 67 CONTRAST MEDIA MARKET, BY END USER, 2024–2031 (USD MILLION) 129 TABLE 68 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 69 DIAGNOSTIC IMAGING CENTERS: CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 70 CONTRAST MEDIA MARKET, BY REGION, 2024–2031 (USD MILLION) 134 TABLE 71 NORTH AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 72 NORTH AMERICA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 136 TABLE 73 NORTH AMERICA: CONTRAST MEDIA MARKET, BY FORM, 2024–2031 (USD MILLION) 136 TABLE 74 NORTH AMERICA: CONTRAST MEDIA MARKET, BY MODALITY, 2024–2031 (USD MILLION) 136 TABLE 75 NORTH AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 137 TABLE 76 NORTH AMERICA: CONTRAST MEDIA MARKET, BY INTRAVASCULAR ROUTE, 2024–2031 (USD MILLION) 137 TABLE 77 NORTH AMERICA: CONTRAST MEDIA MARKET, BY INDICATION, 2024–2031 (USD MILLION) 138 TABLE 78 NORTH AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 138 TABLE 79 NORTH AMERICA: CONTRAST MEDIA MARKET, BY END USER, 2024–2031 (USD MILLION) 138 TABLE 80 US: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 139 TABLE 81 CANADA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 140 TABLE 82 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 83 EUROPE: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 141 TABLE 84 EUROPE: CONTRAST MEDIA MARKET, BY FORM, 2024–2031 (USD MILLION) 142 TABLE 85 EUROPE: CONTRAST MEDIA MARKET, BY MODALITY, 2024–2031 (USD MILLION) 142 TABLE 86 EUROPE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 142 TABLE 87 EUROPE: CONTRAST MEDIA MARKET, BY INTRAVASCULAR ROUTE, 2024–2031 (USD MILLION) 143 TABLE 88 EUROPE: CONTRAST MEDIA MARKET, BY INDICATION, 2024–2031 (USD MILLION) 143 TABLE 89 EUROPE: CONTRAST MEDIA MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 143 TABLE 90 EUROPE: CONTRAST MEDIA MARKET, BY END USER, 2024–2031 (USD MILLION) 144 TABLE 91 GERMANY: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 145 TABLE 92 FRANCE: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 146 TABLE 93 UK: COUNT OF IMAGING ACTIVITY ON NHS PATIENTS, MAY 2023–MAY 2024 147 TABLE 94 UK: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 147 TABLE 95 ITALY: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 148 TABLE 96 SPAIN: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 149 TABLE 97 REST OF EUROPE: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 150 TABLE 98 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 99 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 152 TABLE 100 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY FORM, 2024–2031 (USD MILLION) 152 TABLE 101 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY MODALITY, 2024–2031 (USD MILLION) 152 TABLE 102 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 153 TABLE 103 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY INTRAVASCULAR ROUTE, 2024–2031 (USD MILLION) 153 TABLE 104 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 153 TABLE 105 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY INDICATION, 2024–2031 (USD MILLION) 154 TABLE 106 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY END USER, 2024–2031 (USD MILLION) 154 TABLE 107 CHINA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 155 TABLE 108 JAPAN: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 156 TABLE 109 INDIA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 157 TABLE 110 HIGH CANCER BURDEN AND STRONG HEALTHCARE SPENDING – KEY DEMAND DRIVERS 157 TABLE 111 AUSTRALIA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 158 TABLE 112 SOUTH KOREA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 159 TABLE 113 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 160 TABLE 114 LATIN AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 115 LATIN AMERICA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 161 TABLE 116 LATIN AMERICA: CONTRAST MEDIA MARKET, BY FORM, 2024–2031 (USD MILLION) 161 TABLE 117 LATIN AMERICA: CONTRAST MEDIA MARKET, BY MODALITY, 2024–2031 (USD MILLION) 162 TABLE 118 LATIN AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 162 TABLE 119 LATIN AMERICA: CONTRAST MEDIA MARKET, BY INTRAVASCULAR ROUTE, 2024–2031 (USD MILLION) 162 TABLE 120 LATIN AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 163 TABLE 121 LATIN AMERICA: CONTRAST MEDIA MARKET, BY INDICATION, 2024–2031 (USD MILLION) 163 TABLE 122 LATIN AMERICA: CONTRAST MEDIA MARKET, BY END USER, 2024–2031 (USD MILLION) 163 TABLE 123 BRAZIL: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 164 TABLE 124 MEXICO: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 165 TABLE 125 REST OF LATIN AMERICA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 126 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 127 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 167 TABLE 128 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY FORM, 2024–2031 (USD MILLION) 168 TABLE 129 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY MODALITY, 2024–2031 (USD MILLION) 168 TABLE 130 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 169 TABLE 131 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY INTRAVASCULAR ROUTE, 2024–2031 (USD MILLION) 169 TABLE 132 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 169 TABLE 133 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY INDICATION, 2024–2031 (USD MILLION) 170 TABLE 134 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY END USER, 2024–2031 (USD MILLION) 170 TABLE 135 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 171 TABLE 136 REST OF MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY TYPE, 2024–2031 (USD MILLION) 172 TABLE 137 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CONTRAST MEDIA MARKET, 2022–2025 174 TABLE 138 CONTRAST MEDIA MARKET: DEGREE OF COMPETITION 177 TABLE 139 CONTRAST MEDIA MARKET: REGION FOOTPRINT 185 TABLE 140 CONTRAST MEDIA MARKET: PRODUCT TYPE FOOTPRINT 186 TABLE 141 CONTRAST MEDIA MARKET: MODALITY FOOTPRINT 187 TABLE 142 CONTRAST MEDIA MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 188 TABLE 143 CONTRAST MEDIA MARKET: INDICATION FOOTPRINT 189 TABLE 144 CONTRAST MEDIA MARKET: END USER FOOTPRINT 190 TABLE 145 CONTRAST MEDIA MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SME PLAYERS, BY PRODUCT TYPE, AND REGION 194 TABLE 146 CONTRAST MEDIA MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 195 TABLE 147 CONTRAST MEDIA MARKET: DEALS, JANUARY 2023–JUNE 2026 196 TABLE 148 CONTRAST MEDIA MARKET: EXPANSIONS, JANUARY 2023–JUNE 2026 196 TABLE 149 GE HEALTHCARE: COMPANY OVERVIEW 197 TABLE 150 GE HEALTHCARE: PRODUCTS OFFERED 199 TABLE 151 GE HEALTHCARE: PRODUCT LAUNCHES, JANUARY 2023–JANUARY 2026 199 TABLE 152 BRACCO IMAGING: COMPANY OVERVIEW 201 TABLE 153 BRACCO IMAGING: PRODUCTS OFFERED 201 TABLE 154 BRACCO IMAGING: PRODUCT LAUNCHES, JANUARY 2023–JANUARY 2026 203 TABLE 155 BRACCO IMAGING: DEALS, JANUARY 2023–JANUARY 2026 203 TABLE 156 BAYER AG: COMPANY OVERVIEW 205 TABLE 157 BAYER AG: PRODUCTS OFFERED 206 TABLE 158 BAYER AG: EXPANSIONS, JANUARY 2023–JANUARY 2026 207 TABLE 159 GUERBET : COMPANY OVERVIEW 209 TABLE 160 GUERBET: PRODUCTS OFFERED 210 TABLE 161 GUERBET : PRODUCT APPROVALS, JANUARY 2023–JANUARY 2026 211 TABLE 162 LANTHEUS HOLDINGS, INC.: COMPANY OVERVIEW 213 TABLE 163 LANTHEUS HOLDINGS, INC.: PRODUCTS OFFERED 214 TABLE 164 UNIJULES LIFE SCIENCES LTD.: COMPANY OVERVIEW 216 TABLE 165 UNIJULES LIFE SCIENCES LTD. PRODUCTS OFFERED 217 TABLE 166 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: COMPANY OVERVIEW 218 TABLE 167 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 219 TABLE 168 SANOCHEMIA PHARMAZEUTIKA: BUSINESS OVERVIEW 221 TABLE 169 SANOCHEMIA PHARMAZEUTIKA GMBH : PRODUCTS OFFERED 222 TABLE 170 TAEJOON PHARM CO., LTD.: BUSINESS OVERVIEW 223 TABLE 171 TAEJOON PHARM CO., LTD: PRODUCTS OFFERED 223 TABLE 172 JODAS EXPOIM: BUSINESS OVERVIEW 224 TABLE 173 JODAS EXPOIM : PRODUCTS OFFERED 225 TABLE 174 IMAX DIAGNOSTIC IMAGING LIMITED: BUSINESS OVERVIEW 226 TABLE 175 IMAX DIAGNOSTIC IMAGING LIMITED : PRODUCTS OFFERED 226 TABLE 176 IMAX DIAGNOSTIC IMAGING LIMITED : PIPELINE PRODUCTS 227 TABLE 177 YANGTZE RIVER PHARMACEUTICAL GROUP: BUSINESS OVERVIEW 228 TABLE 178 YANGTZE RIVER PHARMACEUTICAL GROUP: PIPELINE PRODUCTS 229 TABLE 179 LIVEALTH: BUSINESS OVERVIEW 230 TABLE 180 LIVEALTH: PRODUCTS OFFERED 230 TABLE 181 BEIJING BEILU PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW 232 TABLE 182 BEIJING BEILU PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED 232 TABLE 183 BEIJING BEILU PHARMACEUTICAL CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–JANUARY 2026 233 TABLE 184 ARCO LIFESCIENCES (I) PVT. LTD.: COMPANY OVERVIEW 235 TABLE 185 STANEX DRUGS & CHEMICALS PVT. LTD.: COMPANY OVERVIEW 236 TABLE 186 ONKO ILAC SAN. VE TIC. A.S.: COMPANY OVERVIEW 237 TABLE 187 FRESENIUS KABI: COMPANY OVERVIEW 238 TABLE 188 BIEM ILAC SAN. VE: COMPANY OVERVIEW 239 TABLE 189 ADVACARE PHARMA: COMPANY OVERVIEW 240 TABLE 190 FUJIFILM WAKO CHEMICAL CORPORATION: COMPANY OVERVIEW 241 TABLE 191 TRIVITRON HEALTHCARE: COMPANY OVERVIEW 242 TABLE 192 NANOPET PHARMA GMBH: COMPANY OVERVIEW 243 TABLE 193 CONTRAST MEDIA MARKET: RESEARCH ASSUMPTIONS 256 FIGURE 1 CONTRAST MEDIA MARKET SEGMENTATION AND REGIONAL SCOPE 25 FIGURE 2 MARKET SCENARIO 30 FIGURE 3 GLOBAL CONTRAST MEDIA MARKET, 2023–2031 30 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CONTRAST MEDIA MARKET, 2020–2025 31 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF CONTRAST MEDIA MARKET 32 FIGURE 6 HIGH-GROWTH SEGMENTS IN CONTRAST MEDIA MARKET, 2025–2031 33 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CONTRAST MEDIA MARKET DURING FORECAST PERIOD 33 FIGURE 8 CONTRAST MEDIA MARKET DRIVEN BY RISING IMAGING VOLUMES, LOW-DOSE INNOVATIONS, AND EXPANDING ADOPTION ACROSS KEY REGIONS 35 FIGURE 9 NORTH AMERICA TO COMMAND LARGEST MARKET SHARE 36 FIGURE 10 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 37 FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2025 TO 2031 38 FIGURE 12 CONTRAST AGENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39 FIGURE 13 CONTRAST MEDIA MARKET: PORTER’S FIVE FORCES ANALYSIS 50 FIGURE 14 CONTRAST MEDIA MARKET: SUPPLY CHAIN ANALYSIS 55 FIGURE 15 CONTRAST MEDIA MARKET: ECOSYSTEM ANALYSIS 56 FIGURE 16 AVERAGE SELLING PRICE TREND OF CONTRAST MEDIA PRODUCTS, BY REGION, 2026–2024 (USD) 58 FIGURE 17 AVERAGE SELLING PRICE OF CONTRAST MEDIA PRODUCTS, BY KEY PLAYER 60 FIGURE 18 CONTRAST MEDIA MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63 FIGURE 19 CONTRAST MEDIA MARKET: FUNDING SCENARIO, 2019–2023 (USD MILLION) 64 FIGURE 20 NUMBER OF DEALS IN CONTRAST MEDIA MARKET, BY KEY PLAYER, 2019–2023 64 FIGURE 21 VALUE OF DEALS IN CONTRAST MEDIA MARKET, BY KEY PLAYER, 2019–2023 (USD) 65 FIGURE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR CONTRAST MEDIA MARKET, BY PRODUCT 70 FIGURE 23 KEY BUYING CRITERIA FOR END USERS 71 FIGURE 24 CONTRAST MEDIA MARKET: UNMET NEED ANALYSIS 75 FIGURE 25 PATENT ANALYSIS FOR CONTRAST MEDIA MARKET, JANUARY 2015–DECEMBER 2025 78 FIGURE 26 KEY AI USE CASES IN CONTRAST MEDIA ECOSYSTEM 81 FIGURE 27 NORTH AMERICA: CONTRAST MEDIA MARKET SNAPSHOT 135 FIGURE 28 ASIA PACIFIC: CONTRAST MEDIA MARKET SNAPSHOT 151 FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN CONTRAST MEDIA MARKET, 2021–2025 (USD MILLION) 176 FIGURE 30 CONTRAST MEDIA MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 177 FIGURE 31 RANKING OF KEY PLAYERS IN CONTRAST MEDIA MARKET (2024) 179 FIGURE 32 EV/EBITDA OF TOP PLAYERS (2026) 179 FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF TOP PLAYERS (2026) 180 FIGURE 34 CONTRAST MEDIA MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 181 FIGURE 35 CONTRAST MEDIA MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 183 FIGURE 36 CONTRAST MEDIA MARKET: COMPANY FOOTPRINT 184 FIGURE 37 CONTRAST MEDIA MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 192 FIGURE 38 GE HEALTHCARE: COMPANY SNAPSHOT (2025) 198 FIGURE 39 BAYER AG: COMPANY SNAPSHOT (2025) 206 FIGURE 40 GUERBET: COMPANY SNAPSHOT (2025) 210 FIGURE 41 LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT (2025) 214 FIGURE 42 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2025) 219 FIGURE 43 CONTRAST MEDIA MARKET: RESEARCH DATA 244 FIGURE 44 CONTRAST MEDIA MARKET: RESEARCH DESIGN 245 FIGURE 45 PRIMARY SOURCES 248 FIGURE 46 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 249 FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 250 FIGURE 48 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 251 FIGURE 49 CONTRAST MEDIA MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 252 FIGURE 50 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 253 FIGURE 51 DATA TRIANGULATION 255

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

Contrast Media Market By Type (lodinated Contrast Media), Form (Liquid, Powder), Modality (X-ray, MRI, Ultrasound), Route of Administration (Oral, Rectal), Indication (Cancer, Neurological, GI, Musculoskeletal Disorders) & Region - Global Forecast to 2031

授權報價

報告摘要

同分類最新報告（醫療器材）